To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III)

NCT01072942 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Ciprofloxacin (Cipro InhaIe, BAYQ3939)
DRUG: Placebo

Sponsor

Bayer